PE20230494A1 - Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas - Google Patents
Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismasInfo
- Publication number
- PE20230494A1 PE20230494A1 PE2022002607A PE2022002607A PE20230494A1 PE 20230494 A1 PE20230494 A1 PE 20230494A1 PE 2022002607 A PE2022002607 A PE 2022002607A PE 2022002607 A PE2022002607 A PE 2022002607A PE 20230494 A1 PE20230494 A1 PE 20230494A1
- Authority
- PE
- Peru
- Prior art keywords
- proteins
- baff
- april
- methods
- immunomodulatory proteins
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 7
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 239000002955 immunomodulating agent Substances 0.000 title 1
- 229940121354 immunomodulator Drugs 0.000 title 1
- 230000002584 immunomodulator Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 5
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 abstract 2
- 101710178302 Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
En la presente se proporcionan proteinas inmunomoduladoras que exhiben actividad neutralizante de BAFF y APRIL (o heterotrimeros de BAFF/APRIL). Las proteinas inmunomoduladoras proporcionadas en la presente incluyen dominios variantes de Activador Transmembrana e Interactor de CAML (TACI). Entre las proteinas inmunomoduladoras proporcionadas estan las proteinas de fusion de TACI-Fc. Tambien se proporcionan moleculas de acido nucleico que codifican para las proteinas inmunomoduladoras. Las proteinas inmunomoduladoras proporcionan utilidad terapeutica para una variedad de enfermedades, trastornos o condiciones inmunologicas. Tambien se proporcionan composiciones y metodos para producir y utilizar estas proteinas
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063022373P | 2020-05-08 | 2020-05-08 | |
US202063034361P | 2020-06-03 | 2020-06-03 | |
US202063080643P | 2020-09-18 | 2020-09-18 | |
PCT/US2021/031430 WO2021226551A1 (en) | 2020-05-08 | 2021-05-07 | April and baff inhibitory immunomodulatory proteins and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20230494A1 true PE20230494A1 (es) | 2023-03-23 |
Family
ID=76270049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022002607A PE20230494A1 (es) | 2020-05-08 | 2021-05-07 | Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas |
Country Status (15)
Country | Link |
---|---|
US (4) | US20210388054A1 (es) |
EP (2) | EP4146684A2 (es) |
JP (2) | JP2023525033A (es) |
KR (2) | KR20230029622A (es) |
CN (4) | CN116903727A (es) |
AU (2) | AU2021268033A1 (es) |
BR (2) | BR112022022433A2 (es) |
CA (2) | CA3178885A1 (es) |
CL (1) | CL2022003104A1 (es) |
CO (1) | CO2022017780A2 (es) |
IL (2) | IL297981A (es) |
MX (2) | MX2022013999A (es) |
PE (1) | PE20230494A1 (es) |
TW (1) | TW202208414A (es) |
WO (2) | WO2021226551A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA50360A (fr) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences Inc | Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations |
JP2022539785A (ja) * | 2019-12-24 | 2022-09-13 | レメゲン シーオー.,エルティーディー. | TACI-Fc融合タンパク質及びその用途 |
EP4333869A1 (en) * | 2021-05-07 | 2024-03-13 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
WO2023089500A1 (en) * | 2021-11-17 | 2023-05-25 | Aurinia Pharmaceuticals Inc. | B cell activating factor (baff)-a proliferation inducing ligand (april) dual inhibitors |
CA3236667A1 (en) * | 2022-06-08 | 2023-12-14 | Jianmin Fang | Method for treating myasthenia gravis with taci-fc fusion protein |
WO2024044721A1 (en) * | 2022-08-25 | 2024-02-29 | University Of Washington | Injectable recombinant protein-based hydrogels for therapeutic delivery |
WO2024077018A2 (en) * | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
WO2024120458A1 (zh) * | 2022-12-07 | 2024-06-13 | 荣昌生物制药(烟台)股份有限公司 | TACI-Fc融合蛋白液体药物制剂 |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
ATE248924T1 (de) | 1991-05-06 | 2003-09-15 | Us Gov Health & Human Serv | Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
DE69534702T2 (de) | 1994-09-23 | 2006-08-24 | The University Of British Columbia, Vancouver | Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen |
PT784483E (pt) | 1994-10-03 | 2001-05-31 | Us Gov Health & Human Serv | Composicao que compreende um virus recombinante que exprime um antigenio e um virus recombinante que exprime uma molecula imunoestimuladora |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
KR20050004269A (ko) | 1996-10-25 | 2005-01-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 뉴트로킨 알파 |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
US6375952B1 (en) | 1998-08-07 | 2002-04-23 | University Of Washington | Immunological herpes simplex virus antigens and methods for use thereof |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
US20060067933A1 (en) | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
WO2000040716A2 (en) | 1999-01-07 | 2000-07-13 | Zymogenetics, Inc. | Soluble receptor br43x2 and methods of using them for therapy |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
JP4827353B2 (ja) | 1999-08-09 | 2011-11-30 | ターゲティッド ジェネティクス コーポレイション | 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大 |
DE60028830T2 (de) | 2000-02-16 | 2007-01-18 | Genentech, Inc., South San Francisco | Anti-april antikörper und hybridomazellen |
EP1746106A3 (en) | 2000-04-27 | 2007-03-14 | Biogen Idec MA Inc. | Use of TACI as an anti-tumor agent |
AU2001253920B2 (en) | 2000-04-27 | 2006-03-16 | Apoxis Sa | Use of taci as an anti-tumor agent |
US20040013674A1 (en) | 2001-04-27 | 2004-01-22 | Christine Ambrose | Taci as an anti-tumor agent |
CA2408617A1 (en) | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
AU2001282856A1 (en) | 2000-06-15 | 2001-12-24 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
KR20040030628A (ko) | 2001-05-24 | 2004-04-09 | 지모제넥틱스, 인코포레이티드 | Taci-면역글로불린 융합 단백질 |
CA2446734A1 (en) | 2001-05-24 | 2002-11-28 | Human Genome Sciences, Inc. | Antibodies against tumor necrosis factor delta (april) |
PL377119A1 (pl) | 2001-08-03 | 2006-01-23 | Genentech, Inc. | Peptydy TACIs i BR3 i ich zastosowanie |
DK1461073T3 (da) | 2001-11-30 | 2010-03-29 | Us Gov Health & Human Serv | Peptidagonister til prostataspecifikt antigen og anvendelser heraf |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
AU2003256836A1 (en) | 2002-07-25 | 2004-02-16 | Genentech, Inc. | Taci antibodies and uses thereof |
WO2004033486A2 (en) | 2002-10-11 | 2004-04-22 | Zymogenetics, Inc. | Production of homotrimeric fusion proteins |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
EP1578782A4 (en) | 2002-12-30 | 2007-09-12 | Amgen Inc | COSTIMULATING FACTORIAL THERAPY |
US20050163775A1 (en) | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
EP1629001A2 (en) | 2003-06-05 | 2006-03-01 | Genentech, Inc. | Blys antagonists and uses thereof |
BRPI0415709A (pt) | 2003-10-20 | 2006-12-19 | Biogen Idec Inc | esquemas terapêuticos para antagonistas de baff |
PL1718677T3 (pl) | 2003-12-19 | 2012-09-28 | Genentech Inc | Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze |
ES2403055T3 (es) | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
CN101987870B (zh) | 2004-07-15 | 2013-07-03 | 赞科股份有限公司 | 优化的Fc变体 |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
ES2387312T3 (es) | 2004-09-22 | 2012-09-20 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpos IgG4 humanos estabilizados |
MX2007005378A (es) | 2004-11-04 | 2008-02-14 | Genentech Inc | Polipeptidos que ligan a baff y/o april. |
US7550296B2 (en) | 2004-12-01 | 2009-06-23 | Bayer Schering Pharma Ag | Generation of replication competent viruses for therapeutic use |
EA200701211A1 (ru) * | 2004-12-31 | 2007-12-28 | Дженентек, Инк. | Полипептиды, которые связываются с br3, и их применение |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
JP2009507777A (ja) | 2005-08-09 | 2009-02-26 | ザイモジェネティクス,インコーポレイティド | TACI−Ig融合分子を用いたB細胞性腫瘍の処置方法 |
EP1922079A2 (en) | 2005-08-09 | 2008-05-21 | ZymoGenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
EP1924286A4 (en) | 2005-08-12 | 2010-01-13 | Garvan Inst Med Res | PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
US7655439B2 (en) | 2005-09-09 | 2010-02-02 | Zymogenetics, Inc. | Trimerizing polypeptides |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
CA2626082C (en) | 2005-10-13 | 2017-04-11 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
US8784812B2 (en) | 2006-05-15 | 2014-07-22 | Zymogenetics, Inc. | Methods for treating autoimmune diseases using a TACI-Ig fusion molecule |
CA2661872A1 (en) | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Process for the purification of fc-fusion proteins |
FI2061803T4 (fi) | 2006-08-28 | 2023-03-14 | Process for the purification of fc-containing proteins | |
JP2010501622A (ja) | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Fc−融合タンパク質の精製法 |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
JP2010516744A (ja) | 2007-01-26 | 2010-05-20 | メルク セローノ ソシエテ アノニム | 油体技術を用いたFc−融合タンパク質の精製 |
US8852591B2 (en) | 2007-03-27 | 2014-10-07 | Zymogenetics, Inc. | Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease |
SG182191A1 (en) * | 2007-06-13 | 2012-07-30 | Zymogenetics Inc | Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus |
CN101323643B (zh) | 2007-06-15 | 2010-12-01 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
DK2233149T3 (en) | 2007-10-16 | 2016-05-17 | Zymogenetics Inc | COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE |
EP2203465A1 (en) | 2007-10-22 | 2010-07-07 | Merck Serono S.A. | Method for purifying an fc-containing protein |
PL2219675T3 (pl) | 2007-11-12 | 2014-04-30 | Ares Trading Sa | Formulacja dla białek fuzyjnych TACI-immunoglobulina |
US20100239580A1 (en) | 2007-11-12 | 2010-09-23 | Area Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of optic neuritis |
EP2219673A1 (en) | 2007-11-12 | 2010-08-25 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis |
DK2222861T3 (en) | 2007-12-11 | 2018-02-05 | Univ North Carolina Chapel Hill | POLYPURIN-TRACT MODIFIED RETROVIRAL VECTORS |
CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
US8003335B2 (en) | 2008-04-30 | 2011-08-23 | Universite Paris-SUD11 | Levels of APRIL in serum and use in diagnostic methods |
CA2720651C (en) | 2008-05-01 | 2020-03-10 | Zymogenetics, Inc. | Levels of blys/april heterotrimers in serum and use in diagnostic methods |
EP2540740B1 (en) | 2008-06-17 | 2014-09-10 | Apogenix GmbH | Multimeric TNF receptors |
EP2435477A1 (en) | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Antigen-binding proteins |
WO2011109280A1 (en) * | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
CN101851278B (zh) | 2010-05-26 | 2013-03-13 | 石药集团中奇制药技术(石家庄)有限公司 | B细胞激活因子拮抗剂及其制备方法与用途 |
US20110311548A1 (en) | 2010-06-18 | 2011-12-22 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system |
JP6267512B2 (ja) | 2010-09-10 | 2018-01-24 | ティゲニクス、エセ、ア、ウTiGenix,S.A.U. | 幹細胞培養培地および方法 |
CN102085368B (zh) | 2011-01-19 | 2013-06-12 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白用于制备治疗***性红斑狼疮药物的应用 |
CA2830254C (en) | 2011-03-16 | 2019-09-10 | Amgen Inc. | Fc variants |
AU2012243039B2 (en) | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
EP3415528B1 (en) | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
WO2013041029A1 (en) * | 2011-09-23 | 2013-03-28 | Igenimed Pharmaceuticals Inc. | Novel soluble ctla4 variants |
TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Fc融合蛋白及其用途 |
MX366864B (es) | 2012-02-27 | 2019-07-26 | Amunix Operating Inc | Composiciones de conjugados de xten y métodos para realizarlas. |
US10065987B2 (en) | 2013-02-12 | 2018-09-04 | Bristol-Myers Squibb Company | High pH protein refolding methods |
EP3744728A1 (en) | 2013-02-12 | 2020-12-02 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
CN105392801A (zh) | 2013-03-15 | 2016-03-09 | 比奥根Ma公司 | 使用抗αvβ5抗体治疗和预防急性肾损伤 |
CN110903398B (zh) | 2014-01-15 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
US10562954B2 (en) * | 2014-05-12 | 2020-02-18 | Shanghai Kanda Biotechnology Co., Ltd. | Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof |
JP2017522312A (ja) | 2014-07-15 | 2017-08-10 | イミューン デザイン コーポレイション | Tlr4アゴニストアジュバント及びレンチウイルスベクターを用いたプライム・ブーストレジメン |
CA2990177A1 (en) | 2015-06-25 | 2016-12-29 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
BR112018011781A2 (pt) * | 2015-12-14 | 2018-12-04 | Macrogenics Inc | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica |
EP3443000A2 (en) | 2016-04-15 | 2019-02-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
EP3442999A2 (en) | 2016-04-15 | 2019-02-20 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
CA3029197A1 (en) | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
KR20190099194A (ko) | 2016-10-20 | 2019-08-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 분비가능한 변이체 면역조절 단백질 및 조작된 세포 치료 |
EP3596116B1 (en) | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
WO2018170023A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
WO2018236995A2 (en) | 2017-06-20 | 2018-12-27 | Dana-Farber Cancer Institute, Inc. | METHODS FOR MODULATING REGULATORY T LYMPHOCYTES, REGULATORY B LYMPHOCYTES AND IMMUNE RESPONSES USING AVRIL-TACI INTERACTION MODULATORS |
AU2018326805B2 (en) | 2017-09-01 | 2023-11-30 | Dana-Farber Cancer Institute, Inc. | Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer |
MA50360A (fr) * | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences Inc | Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations |
CA3078517A1 (en) | 2017-10-18 | 2019-04-25 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
GB201720426D0 (en) | 2017-12-07 | 2018-01-24 | Hummingbird Bioscience Pte Ltd | CD47 and BCMA antigen-binding molecules |
US20230101432A1 (en) | 2018-01-03 | 2023-03-30 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
MX2020009051A (es) | 2018-03-02 | 2020-12-03 | Allogene Therapeutics Inc | Receptores de citocina quimericos inducibles. |
CN110522908A (zh) | 2018-05-25 | 2019-12-03 | 荣昌生物制药(烟台)有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
US20210363219A1 (en) | 2018-06-15 | 2021-11-25 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
WO2020028572A2 (en) | 2018-08-01 | 2020-02-06 | Unum Therapeutics Inc. | ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF |
WO2020047329A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Chimeric proteins comprising extracellular domains and uses thereof |
JP2022501361A (ja) | 2018-09-19 | 2022-01-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントcd80融合タンパク質および関連構築物の方法および使用 |
CA3117978A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
JP2022510276A (ja) | 2018-11-30 | 2022-01-26 | アルパイン イミューン サイエンシズ インコーポレイテッド | Cd86バリアント免疫調節タンパク質およびその使用 |
WO2020214867A1 (en) | 2019-04-17 | 2020-10-22 | Alpine Immune Sciences, Inc. | Methods and uses of variant icos ligand (icosl) fusion proteins |
CN114728040A (zh) | 2019-06-14 | 2022-07-08 | 科优基因公司 | 新型白介素-2变体及其双功能融合分子 |
EP4056232A4 (en) | 2019-09-13 | 2023-09-13 | Kyowa Kirin Co., Ltd. | DCR3 VARIANT |
BR112021025458A2 (pt) | 2019-12-10 | 2022-06-21 | Remegen Co Ltd | Formulação farmacêutica, método de preparação e uso da mesma |
JP2022539785A (ja) | 2019-12-24 | 2022-09-13 | レメゲン シーオー.,エルティーディー. | TACI-Fc融合タンパク質及びその用途 |
-
2021
- 2021-05-07 AU AU2021268033A patent/AU2021268033A1/en active Pending
- 2021-05-07 KR KR1020227043140A patent/KR20230029622A/ko active Search and Examination
- 2021-05-07 IL IL297981A patent/IL297981A/en unknown
- 2021-05-07 US US17/315,168 patent/US20210388054A1/en active Pending
- 2021-05-07 WO PCT/US2021/031430 patent/WO2021226551A1/en unknown
- 2021-05-07 WO PCT/US2021/031432 patent/WO2021226553A2/en unknown
- 2021-05-07 BR BR112022022433A patent/BR112022022433A2/pt unknown
- 2021-05-07 IL IL297980A patent/IL297980A/en unknown
- 2021-05-07 EP EP21730004.5A patent/EP4146684A2/en active Pending
- 2021-05-07 EP EP21730003.7A patent/EP4146683A1/en active Pending
- 2021-05-07 US US17/923,208 patent/US20230241168A1/en active Pending
- 2021-05-07 MX MX2022013999A patent/MX2022013999A/es unknown
- 2021-05-07 AU AU2021267276A patent/AU2021267276A1/en active Pending
- 2021-05-07 KR KR1020227043139A patent/KR20230029621A/ko active Search and Examination
- 2021-05-07 MX MX2022013998A patent/MX2022013998A/es unknown
- 2021-05-07 CN CN202310582491.4A patent/CN116903727A/zh active Pending
- 2021-05-07 TW TW110116616A patent/TW202208414A/zh unknown
- 2021-05-07 PE PE2022002607A patent/PE20230494A1/es unknown
- 2021-05-07 BR BR112022022524A patent/BR112022022524A2/pt unknown
- 2021-05-07 CN CN202180047833.1A patent/CN115812077A/zh active Pending
- 2021-05-07 CN CN202311249622.3A patent/CN117736297A/zh active Pending
- 2021-05-07 CA CA3178885A patent/CA3178885A1/en active Pending
- 2021-05-07 CN CN202180047593.5A patent/CN116194467A/zh active Pending
- 2021-05-07 CA CA3178882A patent/CA3178882A1/en active Pending
- 2021-05-07 JP JP2022567473A patent/JP2023525033A/ja active Pending
- 2021-05-07 JP JP2022567472A patent/JP2023525032A/ja active Pending
- 2021-06-11 US US17/346,095 patent/US11274140B2/en active Active
-
2022
- 2022-11-08 CL CL2022003104A patent/CL2022003104A1/es unknown
- 2022-12-07 CO CONC2022/0017780A patent/CO2022017780A2/es unknown
-
2023
- 2023-03-17 US US18/186,098 patent/US20240218045A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202208414A (zh) | 2022-03-01 |
CN116903727A (zh) | 2023-10-20 |
JP2023525032A (ja) | 2023-06-14 |
CA3178882A1 (en) | 2021-11-11 |
WO2021226553A3 (en) | 2022-04-28 |
CL2022003104A1 (es) | 2023-07-14 |
US20210388054A1 (en) | 2021-12-16 |
US11274140B2 (en) | 2022-03-15 |
MX2022013998A (es) | 2023-02-16 |
IL297980A (en) | 2023-01-01 |
BR112022022433A2 (pt) | 2022-12-13 |
MX2022013999A (es) | 2023-02-16 |
BR112022022524A2 (pt) | 2022-12-13 |
CN116194467A (zh) | 2023-05-30 |
EP4146683A1 (en) | 2023-03-15 |
CA3178885A1 (en) | 2021-11-11 |
WO2021226551A1 (en) | 2021-11-11 |
IL297981A (en) | 2023-01-01 |
US20210363223A1 (en) | 2021-11-25 |
US20230241168A1 (en) | 2023-08-03 |
AU2021268033A1 (en) | 2022-12-15 |
WO2021226553A2 (en) | 2021-11-11 |
JP2023525033A (ja) | 2023-06-14 |
KR20230029621A (ko) | 2023-03-03 |
CO2022017780A2 (es) | 2023-03-17 |
AU2021267276A1 (en) | 2022-12-15 |
US20240218045A1 (en) | 2024-07-04 |
CN117736297A (zh) | 2024-03-22 |
KR20230029622A (ko) | 2023-03-03 |
EP4146684A2 (en) | 2023-03-15 |
CN115812077A (zh) | 2023-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20230494A1 (es) | Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas | |
ATE509030T1 (de) | Reinigung von fibrinogen | |
NO20063372L (no) | Nye fenylalaninderivater | |
EA200200590A1 (ru) | Производные пирролидина в качестве ингибиторов фосфодиэстеразы, специфичной к циклическому амф | |
EA200601239A1 (ru) | Замещённые хинолиновые соединения | |
EA200501667A1 (ru) | Рецепторный комплекс тканезащитных цитокинов, способы идентификации тканезащитных соединений и их применение | |
CO2023016161A2 (es) | Métodos de dosificación y tratamiento con una proteína inmunomoduladora de fusión taci-fc | |
BRPI0513367A (pt) | arilidenos para o tratamento de doenças mediadas pelo receptor alfa relacionado a estrogênio | |
BRPI0513915A (pt) | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase | |
ME00356B (me) | Novi peptidi koji se vezuju za receptor eritropoietina | |
NO20043612L (no) | Nye fluorenkarboksylsyre-estere, fremgangsmate for fremstilling derav og anvendelse derav som legemidler | |
BRPI0511111A (pt) | compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários | |
EA200870127A1 (ru) | Полициклические производные аминокислот и способы их применения | |
ATE497495T1 (de) | Zur behandlung von neoplastischen erkrankungen, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4- di(phenylamino)pyrimidine | |
BR0307564A (pt) | Derivados de nicotinamida úteis como inibidores de pde4 | |
UY26482A1 (es) | Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales | |
EA200801372A1 (ru) | Способы получения замещенных пиримидинов | |
DK1501507T3 (da) | Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet | |
BRPI0414598A (pt) | indóis substituìdos | |
BRPI0414593A (pt) | derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1 | |
EA200801068A1 (ru) | Производные четвертичного альфа-аминокарбоксамида в качестве модуляторов потенциалозависимых натриевых каналов | |
SV2003001148A (es) | Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv | |
DK1668001T3 (da) | Substituerede heteroarylbenzofuransyrer | |
EA200600735A1 (ru) | Нуклеиновые кислоты, специфично связывающие биоактивный грелин | |
CY1111857T1 (el) | Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης |